News

In connection with the series A financing, Meritage Pharma announced its founding management team: Cam Garner, chairman; Elaine Phillips, president and CEO; Malcolm Hill, chief scientific officer; and

The company is pursuing patent protection on this unique formulation. Outside the US, the company is moving rapidly to secure regulatory approvals, if needed, in those regions where

The company reported that the best nanoviricide anti-HIV drug candidate improved total hours of survival time by 99% with respect to appropriate controls. In contrast, the combo therapy

These new patents are expected to broaden the company’s intellectual property leadership in the field of targeted anti-aminophospholipid agents. Shelley Fussey, vice president of intellectual property at Peregrine,

The company has engaged Cato Research, a global contract research organization (CRO), as a strategic partner and as the CRO to conduct the Phase III clinical program. The

The companies, which are exploring the possibility of a future marketing collaboration in this area, said the collaboration was discontinued due to current technical incompatibilities between Gen-Probe’s nucleic

Joseph Galli, chairman and CEO of Haemacure, said: “We now have the financial resources to execute on all of the necessary milestones to get our fibrin sealant into

Included in the transaction are the rights to a novel formulation of an existing molecule intended to treat an emerging allergic inflammation condition of the gastrointestinal tract. Under

The company expects to grant the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock to cover over-allotments, if any. Luminex intends